CIGB-550-E7(CIGB-550-E7) - _专利_临床

概要

基本信息

药物类型

通用抗原疫苗

别名

Human papillomavirus vaccine(Heber Bio)

靶点-

作用机制

免疫调节剂

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症-

非在研适应症

宫颈癌

原研机构

International Centre for Genetic Engineering and Biotechnology (ICGEB)

在研机构-

非在研机构

Heber Biotec SAInternational Centre for Genetic Engineering and Biotechnology (ICGEB)

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CIGB-550-E7 相关的临床结果

登录后查看更多信息

100 项与 CIGB-550-E7 相关的转化医学

登录后查看更多信息

100 项与 CIGB-550-E7 相关的专利（医药）

登录后查看更多信息

1

项与 CIGB-550-E7 相关的文献（医药）

2019-07-01·Vaccine3区 · 医学

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate

3区 · 医学

Article

作者: Granadillo, Milaid ; Soler, Dayana ; Miyares, Maelys ; Batte, Aileen ; Torrens, Isis ; Blanco, Aracelys ; Urquiza, Dioslaida ; Limonta, Miladys ; Varas, Laura ; Alfonso, Alain B

Cervical cancer is a global public health problem and human papillomavirus (HPV) 16 accounts for approximately 50% of cases worldwide. Although there are several types of HPV therapeutic vaccines in clinical research, there are currently not approved for use in humans. We developed the fusion protein LALF_32-51-E7 (hereafter denominated CIGB550-E7) defined by a cell-penetrating peptide linked to an E7 mutein for the treatment of HPV16-associated tumors. We have demonstrated previously the benefit on antitumor response induced by the immunization with CIGB550-E7 admixed with very small size proteoliposomes (VSSP) adjuvant compared with the adjuvant-free immunization. In this study, we obtained a similar antitumor response in mice immunized with CIGB550-E7 admixed with the new adjuvant sVSSP that does not contain any animal-derived product. Also, the immunization with the above mentioned vaccine preparation induced a cell-mediated immune response. Our results are encouraging for the future clinical trials with the vaccine candidate CIGB550-E7+sVSSP.

100 项与 CIGB-550-E7 相关的药物交易

登录后查看更多信息